Akums Drugs & Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd

Fortune 500 2023
+ 3 More
+ 3 More
OVERVIEW
FINANCIALS

About

Akums Drugs and Pharmaceuticals is an Indian company with a 10% market share in the Indian Contract Development and Market Organisation (CDMO) market as of FY24. It produces effective and safe formulations in multiple dosage forms like that of gummies, liquids, tablets, capsules, and powders. Akums’ services include formulation development, clinical trials, bioequivalence studies, and manufacturing and marketing new fixed-dose combinations and molecules. The company’s business is essentially divided into 4 verticals: nutraceuticals and Ayurveda, pharmaceuticals, cosmetics and derma, and active pharmaceutical ingredients ((APIs). With the help of partners like Apollo Pharmacy, Abbott, and GlaxoSmithKline, Akums is present in more than 60 countries around the world, including Vietnam, Latvia, Tanzania, Kenya, and more.

Incorporation Year: 2004
Headquarters: New Delhi
Top Management: Sandeep Jain/Sanjeev Jain
Industry: Pharma
Website: www.akums.in

Featured In Fortune India Ranking

#487(2023)
Next 500 India
#19(2020)#243(2016)#350(2015)
#19(2020)#243(2016)#350(2015)
Ranking Trend Fortune Next 500 India

Financial Data 2023

Revenue
3,721
(INR Cr)
Net Operating Income
3,655
(INR Cr)
Assets
2,404
(INR Cr)
Profit
95
(INR Cr)
Net Worth
717
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS20232022202120202019201820162015201420132012201120102009
Revenue
(INR Cr)
3721
-1.6%
3782
35.5%
2792
13.0%
2470
229.4%
750
13.4%
662
-60.7%
1683
12.1%
1501
30.2%
1153
41.6%
815
24.4%
655
11.0%
590
41.0%
418
9.3%
383
-
Net Operating Income
(INR Cr)
3655
-0.46%
3672
34.87%
2723
12.78%
2414
0.00%
683
14.65%
596
0.00%
1651
12.75%
1464
28.92%
1136
0.00%
794
22.22%
650
14.17%
569
38.46%
411
8.87%
377
14.87%
Profit
(INR Cr)
95
-
-253
-
123
181.1%
44
-41.7%
75
10.5%
68
10.2%
61
42.7%
43
-51.4%
89
6.6%
83
20.9%
69
11.7%
62
52.8%
40
-7.6%
44
-
Assets
(INR Cr)
2404
14.0%
2109
28.1%
1647
14.5%
1439
56.6%
919
11.4%
825
-7.0%
887
13.5%
781
19.8%
652
28.2%
508
4.4%
487
14.2%
427
38.1%
309
13.5%
272
-
Net Worth
(INR Cr)
717
15.3%
622
-29.7%
885
22.5%
722
0.0%
842
9.7%
767
0.0%
629
27.4%
494
7.8%
458
0.0%
431
23.9%
348
24.6%
279
28.3%
218
22.7%
177
31.3%
Employee Cost
(INR Cr)
590
16.2%
508
19.6%
425
-3.2%
439
325.5%
103
9.5%
94
-70.1%
315
17.3%
268
54.0%
174
130.0%
76
16.3%
65
33.1%
49
54.2%
32
10.4%
29
-
Interest Cost
(INR Cr)
46177204322231012139711
Cash & Bank Balance
(INR Cr)
1501036814740141224306610
Total Debt
(INR Cr)
6193951301755133213255166561361479195

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS20232022202120202019201820162015201420132012201120102009
Profit As % Of Revenues 2.6%-4.4%1.8%10.0%10.2%3.7%2.9%7.7%10.2%10.5%10.4%9.6%11.4%
Profit As % Of Assets 4.0%-7.5%3.0%8.2%8.2%6.9%5.5%13.6%16.3%14.1%14.4%13.0%16.0%
Profit As % Of Networth 13.2%-13.9%6.0%8.9%8.8%9.8%8.7%19.3%19.3%19.8%22.0%18.5%24.6%
Interest Cost to EBITDA % 21.1%-3.0%11.5%4.4%3.6%13.8%17.9%6.9%10.0%13.5%10.3%11.0%18.6%
Debt to Equity Ratio 0.860.640.150.240.060.040.340.520.360.130.390.530.420.53
RONW 19.5%-15.4%6.0%9.3%8.8%9.2%8.5%19.5%25.8%19.8%24.8%18.5%27.9%
ROCE 11.7%-9.4%11.6%9.3%13.3%13.0%14.3%14.3%20.8%27.6%20.5%24.0%19.4%24.1%